Kailera Therapeutics (NASDAQ:KLRA) Shares Down 7% – Should You Sell?

Kailera Therapeutics, Inc. (NASDAQ:KLRA)’s share price fell 7% during trading on Wednesday . The company traded as low as $15.27 and last traded at $15.28. 222,361 shares changed hands during mid-day trading, a decline of 69% from the average session volume of 726,007 shares. The stock had previously closed at $16.43.

Analysts Set New Price Targets

KLRA has been the topic of several research analyst reports. JPMorgan Chase & Co. initiated coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They set an “overweight” rating and a $30.00 price target on the stock. Evercore began coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They issued an “outperform” rating on the stock. Zacks Research upgraded shares of Kailera Therapeutics to a “hold” rating in a research report on Wednesday, May 13th. Jefferies Financial Group began coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They issued a “buy” rating and a $48.00 price target on the stock. Finally, William Blair started coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They set an “outperform” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.75.

Kailera Therapeutics Stock Down 7.4%

The company’s 50 day moving average is $18.32. The company has a market cap of $1.97 billion and a P/E ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA) last released its earnings results on Wednesday, August 12th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.35). Sell-side analysts expect that Kailera Therapeutics, Inc. will post -3.89 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of KLRA. California State Teachers Retirement System bought a new position in Kailera Therapeutics in the 2nd quarter worth $309,000. Tidal Investments LLC bought a new stake in Kailera Therapeutics during the second quarter valued at about $309,000. Squarepoint Ops LLC purchased a new position in shares of Kailera Therapeutics in the second quarter valued at about $993,000. Frazier Life Sciences Management L.P. purchased a new position in shares of Kailera Therapeutics in the second quarter valued at about $24,233,000. Finally, Wellington Management Group LLP bought a new position in shares of Kailera Therapeutics in the second quarter worth about $64,308,000.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.